---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact of diagnostic testing"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact of diagnostic testing. Topics: Payment rates for HLA class I typing and uveal melanoma gene expression profiling on a 2026 state Medicaid laboratory fee schedule; HLA-A∗02:01 test at a U.S. reference laboratory: billing code, method, specimen, and turnaround; HLA-A∗02:01 status recorded in a U.S. real-world cohort; Medicare coverage of gene expression profiling of the primary tumor; 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Payment rates for HLA class I typing and uveal melanoma gene expression profiling on a 2026 state Medicaid laboratory fee schedule

> “This Fee Schedule is effective as of January 1, 2026.”
> “The appearance on this fee schedule of a code and rate is not an indication of coverage, nor a guarantee of payment.”

Source: [Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026)](https://www.chfs.ky.gov/agencies/dms/DMSFeeRateSchedules/2026ClinicalLabRates.pdf)

| Test | Code | Description | Rate |
| --- | --- | --- | --- |
| HLA class I typing, high resolution, one locus | “81380” | “HLA CLASS I TYPING HIGH RESOLUTION ONE LOCUS” | “$177.25” |
| HLA class I typing, high resolution, one allele or allele group | “81381” | “HLA CLASS I TYPING HIGH RESOLUTION ONE ALLELE OR ALLELE GROUP” | “$169.90” |
| Gene expression profiling of uveal melanoma, 15 genes | “81552” | “MRNA GENE EXPRESSION ANALYSIS OF 15 GENES IN EYE MELANOMA O TISSUE OR FINE NEEDLE ASPIRATE” | “$7,776.00” |

Source: [Kentucky Department for Medicaid Services clinical diagnostic laboratory fee schedule (2026)](https://www.chfs.ky.gov/agencies/dms/DMSFeeRateSchedules/2026ClinicalLabRates.pdf)

<a id="topic-2.2.1.8.4-2"></a>

### HLA-A∗02:01 test at a U.S. reference laboratory: billing code, method, specimen, and turnaround

| Item | Labcorp test 167107, HLA A A∗02:01-Specific |
| --- | --- |
| CPT code | “81381” |
| Methodology | “Next Generation Sequencing (NGS), sequence-based typing (SBT) or other DNA methods as needed to achieve desired resolution” |
| Result turnaround time | “3 - 7 days” |
| Specimen | “Whole blood, buccal swabs, spot cards or extracted DNA” |
| Regulatory status | “This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.” |

Source: [Labcorp test 167107, HLA A A*02:01-Specific](https://www.labcorp.com/tests/167107/hla-a-a-02-01-specific)

<a id="topic-2.2.1.8.4-3"></a>

### HLA-A∗02:01 status recorded in a U.S. real-world cohort

> “This retrospective study used the Tempus AI deidentified, multimodal database and included adults diagnosed with mUM from 2019-2025.”
> “Among 219 patients, median age at mUM diagnosis was 65 years; 52.5% were female.”
> “HLA-A*02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%.”

Source: [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states)

<a id="topic-2.2.1.8.4-4"></a>

### Medicare coverage of gene expression profiling of the primary tumor

> “This Medicare contractor will provide limited coverage for the DecisionDx-UM (Castle Bioscience, Inc.) test for the management of newly diagnosed uveal melanoma. This test is intended for the determination of metastatic risk, and to guide surveillance and referral to medical oncology (preferably an oncologist with expertise in melanoma) in patients who have a confirmed diagnosis of uveal melanoma (UM) and no evidence of metastatic disease.”
> “DecisionDx-UM is performed on tissue from a fresh-frozen fine needle aspirate biopsy (FNAB), formalin-fixed paraffin embedded (FFPE) sections from an enucleated tumor, or, in rare cases, fresh-frozen resection material. Results are reported as a 5-year risk classification for metastasis: low risk (Class 1A), intermediate risk (Class 1B), or high risk (Class 2).”

Source: [CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37130)

> “[C]overage for genetic or molecular prognostic testing may vary from payer to payer and require UM patients to go through multiple appeal processes to secure coverage. Medicare covers the DecisionDX-UM test but requires that billing providers utilize a registry and implies a level of oversight on subsequent care, including referrals and follow-up surveillance intensity, which could deter utilization.”

Source: [Haystack Project press release, uveal melanoma Patient Oriented Value report (2022)](https://haystackproject.org/s/Press-Release-UV-POV-vf.pdf)

<a id="topic-2.2.1.8.4-5"></a>

### Medicare payment rate and annual volume of the DecisionDx-UM test

> “DecisionDx-UM tests are processed from our Phoenix laboratory and are covered under LCDs finalized by MAC administrators Palmetto and Noridian in July 2017. We estimate that a significant majority of the DecisionDx-UM tests performed for Medicare patients will meet the coverage criteria.”
> “Our rate for 2023 through 2025 was $7,776 per test and remains $7,776 per test for 2026.”
> “We estimate approximately 2,000 patients in the U.S. are diagnosed annually with UM, representing an estimated U.S. TAM of approximately $10 million.”

Source: [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm)

| DecisionDx-UM test reports delivered | Full year |
| --- | --- |
| Year ended December 31, 2025 | “1,769” |
| Year ended December 31, 2024 | “1,699” |

Source: [Castle Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1447362/000162828026012272/cstl-20251231.htm)

<a id="topic-2.2.1.8.4-6"></a>

### Biopsy, prognostic genetic testing, and out-of-pocket payment reported in a Canadian patient and caregiver survey

> “30.56% of participants reported having a histopathology to confirm melanoma; 25% had a biopsy for monosomy 3; 19.44% had a biopsy for gene expression profiling; and 2.78% reported being unsure of how to answer the question.”
> “This question ascertained whether survey participants had undergone genetic testing to establish their level of metabolic risk.”
> “55.26% of participants responded that yes, they had; 39.47% responded that they had not; 2.63% were unsure; and 2.63% selected other and filled in more details surrounded the details of their genetic testing experience.”
> “53.85% of participants reported that they did not pay for their genetic testing and 46.15% did pay for their genetic testing.”
> “In multiple cases, participants stated that they declined genetic testing because of the cost.”

Source: [Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021)](https://saveyourskin.ca/_files/ugd/e08cdc_41dfa819c12143e2a766b820f9cdeeab.pdf)

<a id="topic-2.2.1.8.4-7"></a>

### Surveillance intensity by metastatic risk class and modeled reduction in surveillance procedures

> “An accurate determination of metastatic risk at diagnosis allows for a risk-appropriate surveillance program.”
> “Patients with low metastatic risk can be removed from this traditional intensive surveillance and instead followed with a low intensity program, such as yearly exams, imaging, and LFTs.”
> “Strict compliance with DecisionDx-UM results was associated with a 50% reduction in the number of surveillance procedures performed at two years compared to the previous framework, and a 63% reduction at five years.”

Source: [CMS Local Coverage Determination L37130, MolDX: DecisionDx-UM (2025)](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37130)

<a id="topic-2.2.1.8.4-8"></a>

### Liver surveillance imaging volume and modeled savings from risk-based screening in the United Kingdom

> “A total of 3854 liver scans were performed on the 615 patients, with a median of 6.2 scans per patient (range, 1–40). Liver MRI was the most performed modality, 2419 scans (63%).”

Source: [Rola et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9102800/)

> “Results showed that at 80% sensitivity, 87% of UM patients will avoid unnecessary radiological scans. This provides potential cost savings of between £46,000 and £97,000 per year to the National Health Service assuming 600 new cases per year.”

Source: [Eleuteri et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33516960/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
